Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland [PDF]
Swiss Medical Weekly, 2023 Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer +5 more
doaj +2 more sources
Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +2 more sources
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák +18 more
doaj +5 more sources
Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors [PDF]
Molecules, 2016 The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj +2 more sources
eNeurologicalSci, 2022 Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides +1 more
doaj +2 more sources
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
Clinical Pharmacology: Advances and Applications, 2015 Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj +2 more sources
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? [PDF]
Advances in Hematology, 2011 The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative.
Ali Zalpour +4 more
doaj +2 more sources
The role of factor Xa inhibitors in venous thromboembolism treatment
Vascular Health and Risk Management, 2015 Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Cabral KP, Ansell JE
doaj +3 more sources
Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review
Thrombosis UpdateHeparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality.
Colton Jones +7 more
doaj +2 more sources
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Journal of Blood Medicine, 2017 Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S +5 more
doaj +1 more source